N-[1-[[2-[[1-[[3,6-bis(3-amino-3-oxopropyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11-tetraoxo-1-oxa-4,7,10-triazacyclotridec-12-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]-11-methyldodecanamide
| Internal ID | 4923e9b3-6d41-4dce-97b7-edf609b100ce |
| Taxonomy | Organic acids and derivatives > Peptidomimetics > Depsipeptides > Cyclic depsipeptides |
| IUPAC Name | N-[1-[[2-[[1-[[3,6-bis(3-amino-3-oxopropyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11-tetraoxo-1-oxa-4,7,10-triazacyclotridec-12-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]-11-methyldodecanamide |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C41H67N11O12/c1-23(2)12-10-8-6-5-7-9-11-13-33(56)52-35(25(4)53)40(62)45-20-34(57)47-24(3)36(58)51-30-21-64-41(63)28(15-17-32(43)55)49-37(59)27(14-16-31(42)54)48-38(60)29(50-39(30)61)18-26-19-44-22-46-26/h19,22-25,27-30,35,53H,5-18,20-21H2,1-4H3,(H2,42,54)(H2,43,55)(H,44,46)(H,45,62)(H,47,57)(H,48,60)(H,49,59)(H,50,61)(H,51,58)(H,52,56) |
| InChI Key | GIRIPBPYVQTCFF-UHFFFAOYSA-N |
| Popularity | 2 references in papers |
| Molecular Formula | C41H67N11O12 |
| Molecular Weight | 906.00 g/mol |
| Exact Mass | 905.49706662 g/mol |
| Topological Polar Surface Area (TPSA) | 365.00 Ų |
| XlogP | -0.40 |
| Atomic LogP (AlogP) | -2.37 |
| H-Bond Acceptor | 13 |
| H-Bond Donor | 11 |
| Rotatable Bonds | 26 |
| There are no found synonyms. |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.7648 | 76.48% |
| Caco-2 | - | 0.8623 | 86.23% |
| Blood Brain Barrier | - | 0.9250 | 92.50% |
| Human oral bioavailability | - | 0.6000 | 60.00% |
| Subcellular localzation | Nucleus | 0.3409 | 34.09% |
| OATP2B1 inhibitior | - | 0.8556 | 85.56% |
| OATP1B1 inhibitior | + | 0.8474 | 84.74% |
| OATP1B3 inhibitior | + | 0.9274 | 92.74% |
| MATE1 inhibitior | - | 0.7809 | 78.09% |
| OCT2 inhibitior | - | 0.9250 | 92.50% |
| BSEP inhibitior | + | 0.9634 | 96.34% |
| P-glycoprotein inhibitior | + | 0.7445 | 74.45% |
| P-glycoprotein substrate | + | 0.8656 | 86.56% |
| CYP3A4 substrate | + | 0.6966 | 69.66% |
| CYP2C9 substrate | + | 0.5979 | 59.79% |
| CYP2D6 substrate | - | 0.8602 | 86.02% |
| CYP3A4 inhibition | - | 0.7465 | 74.65% |
| CYP2C9 inhibition | - | 0.9272 | 92.72% |
| CYP2C19 inhibition | - | 0.9043 | 90.43% |
| CYP2D6 inhibition | - | 0.9246 | 92.46% |
| CYP1A2 inhibition | - | 0.9328 | 93.28% |
| CYP2C8 inhibition | + | 0.6220 | 62.20% |
| CYP inhibitory promiscuity | - | 0.9497 | 94.97% |
| UGT catelyzed | + | 0.6000 | 60.00% |
| Carcinogenicity (binary) | - | 0.8700 | 87.00% |
| Carcinogenicity (trinary) | Non-required | 0.5993 | 59.93% |
| Eye corrosion | - | 0.9866 | 98.66% |
| Eye irritation | - | 0.9008 | 90.08% |
| Skin irritation | - | 0.7771 | 77.71% |
| Skin corrosion | - | 0.9287 | 92.87% |
| Ames mutagenesis | - | 0.6400 | 64.00% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.6535 | 65.35% |
| Micronuclear | + | 0.7100 | 71.00% |
| Hepatotoxicity | - | 0.5445 | 54.45% |
| skin sensitisation | - | 0.8631 | 86.31% |
| Respiratory toxicity | + | 0.8778 | 87.78% |
| Reproductive toxicity | + | 0.9111 | 91.11% |
| Mitochondrial toxicity | + | 0.8000 | 80.00% |
| Nephrotoxicity | - | 0.6957 | 69.57% |
| Acute Oral Toxicity (c) | III | 0.6257 | 62.57% |
| Estrogen receptor binding | + | 0.8156 | 81.56% |
| Androgen receptor binding | + | 0.6484 | 64.84% |
| Thyroid receptor binding | + | 0.5628 | 56.28% |
| Glucocorticoid receptor binding | + | 0.5457 | 54.57% |
| Aromatase binding | + | 0.6334 | 63.34% |
| PPAR gamma | + | 0.7108 | 71.08% |
| Honey bee toxicity | - | 0.7689 | 76.89% |
| Biodegradation | - | 0.7750 | 77.50% |
| Crustacea aquatic toxicity | - | 0.5776 | 57.76% |
| Fish aquatic toxicity | - | 0.4528 | 45.28% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 99.98% | 83.82% |
| CHEMBL230 | P35354 | Cyclooxygenase-2 | 99.93% | 89.63% |
| CHEMBL2581 | P07339 | Cathepsin D | 99.04% | 98.95% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 99.04% | 94.45% |
| CHEMBL2492 | P36544 | Neuronal acetylcholine receptor protein alpha-7 subunit | 98.59% | 88.42% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 97.90% | 96.09% |
| CHEMBL4588 | P22894 | Matrix metalloproteinase 8 | 96.69% | 94.66% |
| CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 96.48% | 85.14% |
| CHEMBL1907594 | P30926 | Neuronal acetylcholine receptor; alpha3/beta4 | 95.97% | 97.23% |
| CHEMBL3038469 | P24941 | CDK2/Cyclin A | 95.49% | 91.38% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 95.10% | 91.11% |
| CHEMBL2094135 | Q96BI3 | Gamma-secretase | 95.07% | 98.05% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 94.96% | 90.08% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 94.29% | 99.17% |
| CHEMBL1937 | Q92769 | Histone deacetylase 2 | 94.20% | 94.75% |
| CHEMBL236 | P41143 | Delta opioid receptor | 94.06% | 99.35% |
| CHEMBL2179 | P04062 | Beta-glucocerebrosidase | 92.82% | 85.31% |
| CHEMBL3038477 | P67870 | Casein kinase II alpha/beta | 92.77% | 99.23% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 92.49% | 95.71% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 92.49% | 95.00% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 92.26% | 90.71% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 92.10% | 93.10% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 91.31% | 97.09% |
| CHEMBL1907589 | P17787 | Neuronal acetylcholine receptor; alpha4/beta2 | 90.96% | 94.55% |
| CHEMBL1255126 | O15151 | Protein Mdm4 | 90.82% | 90.20% |
| CHEMBL325 | Q13547 | Histone deacetylase 1 | 90.80% | 95.92% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 90.57% | 96.90% |
| CHEMBL4296 | Q15858 | Sodium channel protein type IX alpha subunit | 90.08% | 96.11% |
| CHEMBL213 | P08588 | Beta-1 adrenergic receptor | 89.49% | 95.56% |
| CHEMBL2563 | Q9UQL6 | Histone deacetylase 5 | 88.78% | 89.67% |
| CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 88.55% | 97.64% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 87.80% | 97.25% |
| CHEMBL1829 | O15379 | Histone deacetylase 3 | 87.62% | 95.00% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 87.51% | 92.88% |
| CHEMBL1293267 | Q9HC97 | G-protein coupled receptor 35 | 87.34% | 89.34% |
| CHEMBL1075317 | P61964 | WD repeat-containing protein 5 | 87.05% | 96.33% |
| CHEMBL3310 | Q96DB2 | Histone deacetylase 11 | 86.73% | 88.56% |
| CHEMBL1075094 | Q16236 | Nuclear factor erythroid 2-related factor 2 | 86.09% | 96.00% |
| CHEMBL1907600 | Q00535 | Cyclin-dependent kinase 5/CDK5 activator 1 | 84.75% | 93.03% |
| CHEMBL2413 | P32246 | C-C chemokine receptor type 1 | 84.47% | 89.50% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 84.27% | 96.47% |
| CHEMBL1795139 | Q8IU80 | Transmembrane protease serine 6 | 84.20% | 98.33% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 84.01% | 93.56% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 83.45% | 100.00% |
| CHEMBL221 | P23219 | Cyclooxygenase-1 | 82.91% | 90.17% |
| CHEMBL2208 | P49137 | MAP kinase-activated protein kinase 2 | 82.64% | 95.20% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 82.50% | 100.00% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 81.95% | 100.00% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 81.67% | 92.32% |
| CHEMBL1744525 | P43490 | Nicotinamide phosphoribosyltransferase | 81.28% | 96.25% |
| CHEMBL3524 | P56524 | Histone deacetylase 4 | 81.10% | 92.97% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 81.06% | 95.89% |
| CHEMBL4296013 | Q5VWK5 | Interleukin-23 receptor | 80.83% | 88.00% |
| CHEMBL332 | P03956 | Matrix metalloproteinase-1 | 80.70% | 94.50% |
| CHEMBL5261 | Q7L7X3 | Serine/threonine-protein kinase TAO1 | 80.68% | 89.33% |
| CHEMBL259 | P32245 | Melanocortin receptor 4 | 80.20% | 95.38% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 85175698 |
| LOTUS | LTS0256624 |
| wikiData | Q104167202 |